PGR and breast cancer: Administration of synthetic progestin (medroxyprogesterone acetate, MPA), used to mimic hormone replacement therapy, results in mammary tumors whereas treatment with the PR antagonists mifepristone or telapristone acetate suppresses tumorigenesis (Poole et al, 2006; Lanari et al, 2009; Lee et al, 2016).